Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Metadata
Title
Neurodegeneration and neuroprotection in Parkinson disease
Authors
Stanley Fahn
David Sulzer
Publication date
01-01-2004
Publisher
Springer-Verlag
Published in
Neurotherapeutics / Issue 1/2004
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1602/neurorx.1.1.139

Other articles of this Issue 1/2004

Neurotherapeutics 1/2004 Go to the issue

OriginalPaper

Hypoxic preconditioning protects against ischemic brain injury

OriginalPaper

Prophylactic activation of neuroprotective stress response pathways by dietary and behavioral manipulations

OriginalPaper

Failures and successes of NMDA receptor antagonists: Molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults

OriginalPaper

Strategic challenges in neurotherapeutic pharmaceutical development

OriginalPaper

Clinical trials for cytoprotection in stroke

OriginalPaper

Neuroprotection and acute spinal cord injury: A reappraisal